Evidence map›Paper›PMID 30833431›Full record

ArticleAntimicrobial agents and chemotherapy2019

Pep5, a Fragment of Cyclin D2, Shows Antiparasitic Effects in Different Stages of the

Christiane Bezerra de Araujo, Loyze Paola de Lima, Simone Guedes Calderano, Flávia Silva Damasceno, Ariel M Silber, Maria Carolina Elias

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Pep5-Cpp, a Cyclin D2-Derived Antimicrobial.Molecules (Basel, Switzerland) · 2026
    Article
  3. Peptidome: Chaos or Inevitability.International journal of molecular sciences · 2021
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Christiane Bezerra de AraujoLaboratório Especial de Ciclo Celular, Instituto Butantan, São Paulo, Brazil chris.biologia@gmail.com carolina.eliassabbaga@butantan.gov.br.
Loyze Paola de LimaLaboratório Especial de Ciclo Celular, Instituto Butantan, São Paulo, Brazil.
Simone Guedes CalderanoLaboratório de Parasitologia, Instituto Butantan, São Paulo, Brazil.
Flávia Silva DamascenoLaboratory of Biochemistry of Tryps (LaBTryps), Departamento de Parasitologia, Instituto de Ciências Biomédicas, São Paulo, Brazil.
Ariel M SilberLaboratory of Biochemistry of Tryps (LaBTryps), Departamento de Parasitologia, Instituto de Ciências Biomédicas, São Paulo, Brazil.
Maria Carolina EliasLaboratório Especial de Ciclo Celular, Instituto Butantan, São Paulo, Brazil chris.biologia@gmail.com carolina.eliassabbaga@butantan.gov.br.
Instituto Butantan · BR

Funding

Medical Research Council MR/P027989/1
6 · The paper itself

Abstract

Pep5 (WELVVLGKL) is a fragment of cyclin D2 that exhibits a 2-fold increase in the S phase of the HeLa cell cycle. When covalently bound to a cell-penetrating peptide (Pep5-cpp), the nonapeptide induces cell death in several tumor cells, including breast cancer and melanoma cells. Additionally, Pep5-cpp reduces the

Indexed as

CalciumCell DeathChromatography, AffinityCyclin D2HeLa CellsHumansLife Cycle StagesMass SpectrometryTrypanosoma cruziCalciumCyclin D2cell deathpeptide 5Trypanosoma cruzi

Identifiers

PMID30833431
PMCPMC6496079
OpenAlexW2919795415

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.